SCHEMBL29310042

SCHEMBL29310042

CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NC(C(=O)N[C@H](C=O)CC(=O)O)C(C)C

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CASP1 P29466 5/20 0.50
CASP3 P42574 3/20 0.50
CASP9 P55211 3/20 0.50
CASP7 P55210 1/20 0.50
GNPAT O15228 1/20 0.43
TASP1 Q9H6P5 1/20 0.43
ENPEP Q07075 5/20 0.42
BACE1 P56817 4/20 0.41
BACE2 Q9Y5Z0 2/20 0.41
CASP4 P49662 1/20 0.41
CASP5 P51878 1/20 0.41
CASP6 P55212 1/20 0.41
CASP8 Q14790 1/20 0.41
CASP10 Q92851 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.39
BMP1 P13497 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1674857 1.00 CASP1 (0.50) CASP1CASP3CASP9CASP7GNPAT
SCHEMBL13194679 1.00 CASP1 (0.50) CASP1CASP3CASP9CASP7GNPAT
SCHEMBL4100803 1.00 CASP1 (0.50) CASP1CASP3CASP9CASP7GNPAT
SCHEMBL10068454 0.98 CASP1 (0.47) CASP1CASP3CASP9CASP7GNPAT
SCHEMBL29802264 0.93 TASP1 (0.51) CASP1CASP3CASP9CASP7TASP1
SCHEMBL20257260 0.91 TASP1 (0.53) CASP1CASP3CASP9CASP7TASP1
SCHEMBL20257263 0.91 TASP1 (0.53) CASP1CASP3CASP9CASP7TASP1
SCHEMBL29664642 0.87 CASP1 (0.47) CASP1CASP3CASP9CASP7ENPEP
SCHEMBL23133189 0.87 CASP1 (0.49) CASP1CASP3CASP9CASP7GNPAT
SCHEMBL23133187 0.87 CASP1 (0.49) CASP1CASP3CASP9CASP7GNPAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240229043-A1 Methods and Compositions for Treating, Ameliorating, and/or Preventing Chronic Kidney Disease (CKD) and Complications thereof by Regulating DPEP1, CASP9, ACSS2 and/or FASN UNIV PENNSYLVANIA (US) 2024-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240229043-A1 Methods and Compositions for Treating, Ameliorating, and/or Preventing Chronic Kidney Disease (CKD) and Complications thereof by Regulating DPEP1, CASP9, ACSS2 and/or FASN FASN, CASP9, AIFM2 CASP1 6/4885CASP3 26/4885CASP9 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.